Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,400 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 5 February 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download: 

(PDF, 3MB, 197 pages)

 

Export 31 results:
Author Title Type [ Year(Asc)]
Filters: Author is Currie, C. J.  [Clear All Filters]
2019
L. A. Scott, Jones, B. I., Berni, T. R., Berni, E. R., De Vries, J., and Currie, C. J., “Evaluation of the epidemiology of peanut allergy in the United Kingdom”, Expert Rev Clin Immunol, vol. 15, pp. 1333-1339, 2019.
L. A. Scott, Berni, T. R., Berni, E. R., De Vries, J., and Currie, C. J., “Evaluation of the healthcare resource use and the related financial costs of managing peanut allergy in the United Kingdom”, Expert Rev Clin Immunol, vol. 15, pp. 889-896, 2019.
E. R. Berni, Jones, B. I., Berni, T. R., Whitehouse, J., Hudson, M., Orr, J., Conway, P., Amlani, B., and Currie, C. J., “The Model of Mortality with Incident Cirrhosis (MoMIC) and the model of Long-term Outlook of Mortality in Cirrhosis (LOMiC)”, PLoS One, vol. 14, p. e0223253, 2019.
2018
C. L. Morgan, Qiao, Q., Grandy, S., Johnsson, K., Jenkins-Jones, S., Holden, S., and Currie, C. J., “Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study”, Diabetes Ther, vol. 9, pp. 269-283, 2018.
C. J. Currie, Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Voss, B., Rajpathak, S. N., Alemayehu, B., Peters, J. R., and Engel, S. S., “Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival”, Diabetes Obes Metab, vol. 20, pp. 821-830, 2018.
C. L. Morgan, Inzucchi, S. E., Puelles, J., Jenkins-Jones, S., and Currie, C. J., “Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis”, Diabetes Obes Metab, vol. 20, pp. 2140-2147, 2018.
S. Jenkins-Jones, Parviainen, L., Porter, J., Withe, M., Whitaker, M. J., Holden, S. E., Morgan, C. L., Currie, C. J., and Ross, R. J. M., “Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia”, Eur J Endocrinol, vol. 178, pp. 309-320, 2018.
2017
T. Holbrook, Tang, Y., Das, R., Shankar, R. R., Tunceli, K., Williams, J., Radican, L., Holden, S. E., Morgan, C. L., Piercy, J., and Currie, C. J., “Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study”, Int J Clin Pract, vol. 71, 2017.
S. E. Holden, Morgan, C. L., Qiao, Q., Jenkins-Jones, S., Berni, E. R., and Currie, C. J., “Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study”, Diabetes Obes Metab, vol. 19, pp. 1097-1105, 2017.
S. E. Holden, Jenkins-Jones, S., Morgan, C. L., Peters, J. R., Schernthaner, G., and Currie, C. J., “Prevalence, glucose control and relative survival of people with Type 2 diabetes in the UK from 1991 to 2013”, Diabet Med, vol. 34, pp. 770-780, 2017.
E. Berni, de Voogd, H., Halcox, J. P., Butler, C. C., Bannister, C. A., Jenkins-Jones, S., Jones, B., Ouwens, M., and Currie, C. J., “Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study”, BMJ Open, vol. 7, p. e013398, 2017.
2016
S. E. Holden, Jenkins-Jones, S., and Currie, C. J., “Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study”, PLoS One, vol. 11, p. e0153594, 2016.
E. Berni, Butler, C. C., Jenkins-Jones, S., de Voogd, H., Ouwens, M., Morgan, C. L., and Currie, C. J., “Comparative estimated effectiveness of antibiotic classes as initial and secondary treatments of respiratory tract infections: longitudinal analysis of routine data from UK primary care 1991-2012”, Curr Med Res Opin, vol. 32, pp. 1023-32, 2016.
E. Berni, Scott, L. A., Jenkins-Jones, S., de Voogd, H., Rocha, M. S., Butler, C. C., Morgan, C. L., and Currie, C. J., “Non-Response to Antibiotic Treatment in Adolescents for Four Common Infections in UK Primary Care 1991-2012: A Retrospective, Longitudinal Study”, Antibiotics (Basel), vol. 5, 2016.
2015
G. Baxter, Morgan, C. L., Jenkins-Jones, S., Currie, C. J., and Schultewolter, D., “Association of Adverse Events And Health Service Usage With Tapentadol Prolonged-Release Treatment Compared With Morphine Controlled-Release (Cr) And Oxycodone Cr: A Uk Primary Care Observational Study”, Value Health, vol. 18, p. A658, 2015.
S. E. Holden, Jenkins-Jones, S., Morgan, C. L., Schernthaner, G., and Currie, C. J., “Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer”, Diabetes Obes Metab, vol. 17, pp. 350-62, 2015.
2014
C. J. Currie, Berni, E., Jenkins-Jones, S., Poole, C. D., Ouwens, M., Driessen, S., de Voogd, H., Butler, C. C., and Morgan, C. L., “Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis”, Bmj, vol. 349, p. g5493, 2014.
C. L. Morgan, Mukherjee, J., Jenkins-Jones, S., Holden, S. E., and Currie, C. J., “Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study”, Diabetes Obes Metab, vol. 16, pp. 957-62, 2014.
C. A. Bannister, Holden, S. E., Jenkins-Jones, S., Morgan, C. L., Halcox, J. P., Schernthaner, G., Mukherjee, J., and Currie, C. J., “Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls”, Diabetes Obes Metab, vol. 16, pp. 1165-73, 2014.
C. L. Morgan, Mukherjee, J., Jenkins-Jones, S., Holden, S. E., and Currie, C. J., “Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality”, Diabetes Obes Metab, vol. 16, pp. 977-83, 2014.
C. L. Morgan, Puelles, J., Poole, C. D., and Currie, C. J., “The effect of withdrawal of rosiglitazone on treatment pathways, diabetes control and patient outcomes: a retrospective cohort study”, J Diabetes Complications, vol. 28, pp. 360-4, 2014.
C. A. Bannister, Poole, C. D., Jenkins-Jones, S., Morgan, C. L., Elwyn, G., Spasic, I., and Currie, C. J., “External validation of the UKPDS risk engine in incident type 2 diabetes: a need for new type 2 diabetes-specific risk equations”, Diabetes Care, vol. 37, pp. 537-45, 2014.
S. E. Holden, Gale, E. A., Jenkins-Jones, S., and Currie, C. J., “How many people inject insulin? UK estimates from 1991 to 2010”, Diabetes Obes Metab, vol. 16, pp. 553-9, 2014.
2013
S. H. Holden, Barnett, A. H., Peters, J. R., Jenkins-Jones, S., Poole, C. D., Morgan, C. L., and Currie, C. J., “The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010”, Diabetes Obes Metab, vol. 15, pp. 844-52, 2013.
C. J. Currie, Poole, C. D., Evans, M., Peters, J. R., and Morgan, C. L., “Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes”, J Clin Endocrinol Metab, vol. 98, pp. 668-77, 2013.
C. D. Poole, Halcox, J. P., Jenkins-Jones, S., Carr, E. S., Schifflers, M. G., Ray, K. K., and Currie, C. J., “Omega-3 Fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study”, Clin Ther, vol. 35, pp. 40-51, 2013.
S. E. Holden, Jenkins-Jones, S., Poole, C. D., Morgan, C. L., Coghill, D., and Currie, C. J., “The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010)”, Child Adolesc Psychiatry Ment Health, vol. 7, p. 34, 2013.
C. L. Morgan, Owens, D. R., Aubonnet, P., Carr, E. S., Jenkins-Jones, S., Poole, C. D., and Currie, C. J., “Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study”, BMJ Open, vol. 3, p. e004025, 2013.
2012
C. L. Morgan, Jenkins-Jones, S., Currie, C. J., and Rees, D. A., “Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study”, J Clin Endocrinol Metab, vol. 97, pp. 3251-60, 2012.
C. L. Morgan, Poole, C. D., Evans, M., Barnett, A. H., Jenkins-Jones, S., and Currie, C. J., “What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes”, J Clin Endocrinol Metab, vol. 97, pp. 4605-12, 2012.
2010
C. J. Currie, Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., and Poole, C. D., “Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study”, Lancet, vol. 375, pp. 481-9, 2010.
[Page last reviewed 5 February 2020]